491 related articles for article (PubMed ID: 30352857)
1. The mechanism of resistance to favipiravir in influenza.
Goldhill DH; Te Velthuis AJW; Fletcher RA; Langat P; Zambon M; Lackenby A; Barclay WS
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):11613-11618. PubMed ID: 30352857
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.
Komeno T; Furuta Y; Nakajima N; Tani H; Morinaga Y
Antiviral Res; 2022 Sep; 205():105387. PubMed ID: 35931138
[TBL] [Abstract][Full Text] [Related]
3. Favipiravir-resistant influenza A virus shows potential for transmission.
Goldhill DH; Yan A; Frise R; Zhou J; Shelley J; Gallego Cortés A; Miah S; Akinbami O; Galiano M; Zambon M; Lackenby A; Barclay WS
PLoS Pathog; 2021 Jun; 17(6):e1008937. PubMed ID: 34061908
[TBL] [Abstract][Full Text] [Related]
4. Characterization of susceptibility variants of influenza virus grown in the presence of T-705.
Daikoku T; Yoshida Y; Okuda T; Shiraki K
J Pharmacol Sci; 2014; 126(3):281-4. PubMed ID: 25296868
[TBL] [Abstract][Full Text] [Related]
5. Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.
Vanderlinden E; Vrancken B; Van Houdt J; Rajwanshi VK; Gillemot S; Andrei G; Lemey P; Naesens L
Antimicrob Agents Chemother; 2016 Nov; 60(11):6679-6691. PubMed ID: 27572398
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
Abdelnabi R; Morais ATS; Leyssen P; Imbert I; Beaucourt S; Blanc H; Froeyen M; Vignuzzi M; Canard B; Neyts J; Delang L
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381577
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.
Sangawa H; Komeno T; Nishikawa H; Yoshida A; Takahashi K; Nomura N; Furuta Y
Antimicrob Agents Chemother; 2013 Nov; 57(11):5202-8. PubMed ID: 23917318
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
10. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K; Mishin VP; Deyde VM; Furuta Y; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2010 Jun; 54(6):2517-24. PubMed ID: 20350949
[TBL] [Abstract][Full Text] [Related]
11. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.
Baranovich T; Wong SS; Armstrong J; Marjuki H; Webby RJ; Webster RG; Govorkova EA
J Virol; 2013 Apr; 87(7):3741-51. PubMed ID: 23325689
[TBL] [Abstract][Full Text] [Related]
12. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
14. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity.
Su CY; Cheng TJ; Lin MI; Wang SY; Huang WI; Lin-Chu SY; Chen YH; Wu CY; Lai MM; Cheng WC; Wu YT; Tsai MD; Cheng YS; Wong CH
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19151-6. PubMed ID: 20974907
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Baz M; Carbonneau J; Rhéaume C; Cavanagh MH; Boivin G
Viruses; 2018 Nov; 10(11):. PubMed ID: 30400276
[TBL] [Abstract][Full Text] [Related]
17. Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir.
Daikoku T; Mizuguchi M; Obita T; Yokoyama T; Yoshida Y; Takemoto M; Shiraki K
J Microbiol Immunol Infect; 2018 Oct; 51(5):581-586. PubMed ID: 28709841
[TBL] [Abstract][Full Text] [Related]
18. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
[TBL] [Abstract][Full Text] [Related]
19.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
20. Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing.
Goldhill DH; Langat P; Xie H; Galiano M; Miah S; Kellam P; Zambon M; Lackenby A; Barclay WS
J Virol; 2019 Jan; 93(2):. PubMed ID: 30381482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
